Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorundrostat in Uncontrolled and Resistant Hypertension
NCT06153693Phase 3Completed
- Sponsor
- Mineralys Therapeutics
- Start
- Nov 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial of lorundrostat in resistant hypertension (RH) (3 arms), sponsored by Mineralys Therapeutics. Primary endpoint: Change from baseline in automated office blood pressure systolic blood pressure at 6 weeks. Started Nov 2023; status: completed.
02
Drugs
lorundrostat
03
Conditions
resistant hypertension (RH)
Beyond the preview
Go deeper on NCT06153693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06153693.